FDA Issues CRL for Oxylanthanum Carbonate - Top-Institutions - MDSpire

FDA Issues CRL for Oxylanthanum Carbonate

The action relates to previously identified third-party manufacturing deficiencies rather than concerns about the clinical efficacy or safety data, according to the company.

  • By

  • Kathryn Wighton

  • June 30, 2026

  • 2 min

Share

Top Institutions in Internal Medicine

Brief introduction explaining scope and methodology.

  • #1

    Stanford University School of Medicine / Stanford Health Care
    Stanford University School of Medicine / Stanford Health Care

    Stanford, California

    Key Differentiators

    • Nephrology
    • Pharmacology

  • #2

    Renal Associates, P.A. (Clinical Advancement Center)
    Renal Associates, P.A. (Clinical Advancement Center)

    San Antonio, Texas

    Key Differentiators

    • Nephrology

  • #3

    Centre for Vision Research
    Centre for Vision Research

    Sydney, New South Wales

    Key Differentiators

    • Ophthalmology
    • Pharmacology

Original Source(s)

FDA Issues CRL for Oxylanthanum Carbonate

  • by Kathryn Wighton

  • June 30, 2026

Related Content

FDA Expands CAPVAXIVE Pediatric Use

Phase 3 data showed noninferior immune responses vs pneumococcal 23-valent polysaccharide vaccine in pediatric patients at increased risk.

Can Finerenone Alter Glomerular Disease Trajectory?

A prespecified exploratory analysis of the FIND-CKD clinical trial examined kidney function, albuminuria, and kidney failure outcomes in 903 patients with glomerular diseases.

FDA Monthly Preview: Key June Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.